- Avalon Ventures announced it entered a deal with GlaxoSmithKline for the acquisition of Sitari Pharmaceuticals by GSK. These are the details behind the deal.
Avalon Ventures recently announced that it entered a definitive agreement with GlaxoSmithKline (GSK) for the acquisition of Sitari Pharmaceuticals by GSK. Sitari is known for developing a novel treatment for celiac disease and it was the first company formed under the GSK-Avalon venture collaboration in 2013. Sitari was incubated at COI Pharmaceuticals — which is the Community of Innovation established by Avalon Ventures. The terms of the deal were undisclosed
“Our collaboration with GSK has been overwhelmingly positive as we were able to rapidly launch a series of new companies based on promising scientific research, and we successfully advanced five programs into preclinical studies for a variety of unmet medical needs,” said Jay Lichter, Ph.D. — who is the CEO of Sitari, president and CEO of COI, and managing director of Avalon Ventures. “Sitari’s preclinical program has the potential to become a medicine to help millions of patients with celiac disease, and we are excited that GSK, a leader in developing innovative medicines, will be advancing the program.”
Genetic predisposition is known for playing a key role in celiac disease — which is an autoimmune digestive disorder caused by intolerance to gluten (a protein found in wheat, rye, and barley that damages the small intestine and interferes with absorption of nutrients from food).
The enzymatic activity of transglutaminase 2 (TG2) is responsible for triggering the inflammatory cascade in response to gluten exposure in patients with celiac disease. And Sitari’s TG2 inhibitors have the potential to suppress the autoimmune response that results in intestinal inflammation and cell pathogenesis in celiac patients.
“Over the last six years, GSK and Avalon have pioneered a unique biotech funding model designed to identify novel targets from top-tier academic labs and translate cutting-edge discoveries into promising clinical candidates,” said John Lepore, the SVP of Research at GSK. “Bringing the Sitari TG2 program into GSK is strongly aligned with our research focus on genetically-associated targets and immune-driven disease. The current standard of care for celiac disease is strict adherence to a gluten-free diet, but a significant number of patients still experience gastrointestinal symptoms and disease progression. TG2 inhibition could represent a new hope for celiac disease patients.”
This is a first-of-its-kind collaboration between Avalon Ventures and GSK combined Avalon’s successful approach of investing in early-stage life science innovation with GSK’s expertise and resources in drug discovery and development. And the 8 companies that were formed under the collaboration were incubated at COI Pharmaceuticals where they received access to executive leadership and operational management.
As part of the agreement, GSK had acquired Sitari and all of its intellectual property.
